Background

Prion diseases, also referred to as transmissible spongiform encephalopathies (TSE), are a rare group of progressive neurodegenerative disorders that can occur in humans and animals. Prion diseases can be sporadic, inherited, iatrogenic, or acquired. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. It is a rare, fatal disease commonly characterized by rapidly progressing dementia, poor balance, visual changes and/or muscle jerks. Sporadic CJD (sCJD) has no known cause and accounts for about 85% of all CJD cases. Familial CJD (fCJD) results from an inherited mutation and accounts for 10–15% of cases.

In 1996, a new variant CJD (vCJD) recognized in the United Kingdom was associated with eating cattle products from cows affected with bovine spongiform encephalopathy (“mad cow disease”). To date, no cases of variant CJD are thought to have been acquired in Washington or the United States.

Iatrogenic transmission of the CJD agent (iCJD) has been linked to the use of contaminated human growth hormone (hGH), dura mater and corneal grafts, or neurosurgical equipment. All of the equipment-related cases occurred before the implementation of the routine sterilization procedures currently used in health care facilities. No equipment-related cases have been reported since 1976. In the United States, 29 iCJD cases have been linked to the use of pituitary hGH in patients treated before 1977. The growth hormone currently used for treatment poses no threat of infection with CJD.

The only available method for confirming the diagnosis of prion diseases is the pathologic examination of brain tissue (autopsy or biopsy). Clinical symptoms, in conjunction with some non-confirmatory diagnostic tests (RT-QuIC, 14-3-3 protein in cerebrospinal fluid, MRI, and EEG), can be used to make a clinical diagnosis of probable CJD.

Annual Summary

Prion disease test results for 99 individuals were received by DOH during 2022. Of these, 82 were not suggestive of prion disease. Follow-up investigation for 17 patients with at least one positive* laboratory result revealed that 11 were diagnosed with a different condition, or on further investigation symptoms were inconsistent with CJD. One case met the definition for a possible case. The remaining 5 patients met the CDC criteria for definite or probable cases. Of the 6 cases meeting the definition of definite, probable or possible, 5 died in 2022.
Washington prion disease surveillance overview, 2022

Persons for whom test results were received: 99

Results negative: 82
At least 1 positive result: 17*

Not investigated

Definite: 2
Probable: 3
Possible: 1
Not a Case: 11

Characteristics of Washington CJD cases, 2022

Females comprised 40% of cases.

The median age at diagnosis was 69 years (range: 48-79).

The median time between onset of symptoms and death was 3 months (range: 1-12 months).

Confirmatory pathologic testing (biopsy and/or autopsy) was performed in 40% of the cases.

No iatrogenic or variant CJD was reported.

The incidence of CJD in Washington State in 2022 was 0.64 cases/million population.

The average worldwide occurrence of CJD is approximately 1–2 cases/million population per year.

Prion deaths by county, 2022

County    N
Spokane  1
Benton-Franklin  1
Mason  1
Pierce  1
King  1
Total  5

Table 1. CSF and confirmatory pathology testing in Washington State residents who died of prion disease, 2022

<table>
<thead>
<tr>
<th>Case</th>
<th>CSF test</th>
<th>T-tau</th>
<th>14-3-3</th>
<th>RT-QuIC*</th>
<th>Autopsy</th>
<th>CJD type</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Not Done</td>
<td>Not Done</td>
<td>Not Done</td>
<td>Not Done</td>
<td>no</td>
<td>Possible sporadic</td>
<td>possible</td>
</tr>
<tr>
<td>2</td>
<td>NPDPSC</td>
<td>&gt;20,000</td>
<td>47,805</td>
<td>positive</td>
<td>yes</td>
<td>Sporadic</td>
<td>definite</td>
</tr>
<tr>
<td>3</td>
<td>NPDPSC</td>
<td>13,228</td>
<td>49,972</td>
<td>positive</td>
<td>yes</td>
<td>Sporadic</td>
<td>definite</td>
</tr>
<tr>
<td>4</td>
<td>NPDPSC</td>
<td>&gt;20,000</td>
<td>&gt;160,000</td>
<td>Not Done</td>
<td>no</td>
<td>Presumed sporadic</td>
<td>probable</td>
</tr>
<tr>
<td>5</td>
<td>NPDPSC</td>
<td>6,257</td>
<td>25,672</td>
<td>positive</td>
<td>yes</td>
<td>Presumed sporadic</td>
<td>probable</td>
</tr>
</tbody>
</table>

* A positive biopsy/autopsy result or a CSF test with a positive result for a RT-QuIC, or a highly elevated 14-3-3 or T-Tau, or a positive test on anyone under 55 on any of the three diagnostic tests.

CJD deaths by age, sex, type, and case classification (n=5) Washington State, 2022

DOH 420-161, Published: September 6, 2023
*RT-QuIC (Real Time Quaking-Induced Conversion) became available in April 2015 at NPDPSC. It was performed as a reflex test following a positive 14-3-3 protein or T-tau with a value of 500 pg/mL or higher 2015-2019. RT-QuIC is performed on all samples beginning January 2019.

**CJD Case Definitions**
For sporadic, familial, iatrogenic, and variant CJD case definitions please see:
http://www.cdc.gov/prions/cjd/diagnostic-criteria.html
http://www.cdc.gov/prions/vcjd/diagnostic-criteria.html